In a novel, integrated platform, integration of human bone tumor and cardiac tissues improved predictive accuracy of linsitinib efficacy and safety. This platform mimicked clinical trial results, unlike other pre-clinical models.
For metastatic colonization to occur, disseminated tumor cells must survive, adapt to, and remodel distant microenvironments in an organ-specific manner. We established a human multitissue model of cancer spread, with engineered bone and lung linked by vascular flow containing circulating cancer cells. Parental MDA-MB-231 cells extravasated toward both tissues, remodeled their niches, and acquired transcriptional programs reflecting adaptation to the local microenvironment, particularly upon homing to bone. Tissue-specific colonization by the bone- and lung-tropic MDA-MB-231 derivatives was quantified in independently perfused bone or lung platforms. Consistent with in vivo behavior, bone-tropic cells showed stronger bone colonization than lung-tropic cells and induced more pronounced osteolysis. In contrast, lung-tropic cells caused greater epithelial disruption in lung tissue and only modest colonization of bone. Distinct patterns of tissue colonization and secreted factors demonstrate that this device recapitulates key features of organ-specific metastasis observed in vivo for this family of cell lines.
The 5-year survival rates for metastatic breast cancer are stuck at <30%. The plateauing of progress suggests the need for improved, dynamic, 3D, and human models of this multi-tissue process. Breast cancer metastasis also tends to have a subtype dependent organotropism. Here we show that using a novel organs-on-a-chip platform we have been able to recapitulate the multiple stages of both multi-tissue and tissue-specific breast cancer metastasis for the first time in an entirely human in vitro model.